4503.T
Astellas Pharma Inc.
プライム · 医薬品 · 医薬品 · JP
JPY 2,417.00
+1.15%Year over year
Reported trailing growth
- Revenue
- +11.9%
- EBITDA
- —
- EBIT
- +832.4%
- EPS
- +474.4%
- Free cash flow
- +219.0%
- Operating cash flow
- +188.0%
Forward estimates
Based on analyst estimates
- Revenue
- -1.8%
- EBITDA
- —
- EPS
- -14.3%
Three-year CAGR
- Revenue
- +12.1%
- EBITDA
- —
- EBIT
- +42.2%
- Net income
- +43.5%
- EPS
- +44.2%
- Free cash flow
- +19.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026